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ABSTRACT
Background. When invasive components are discovered
at mastectomy for vacuum-assisted biopsy (VAB)-diag-
nosed ductal carcinoma in situ (DCIS), the only option
available is axillary lymph node dissection (ALND). The
primary aim of this prospective multicenter trial was to
determine the benefit of performing upfront sentinel lymph
node (SLN) biopsy for these patients. The secondary aim
was to determine DCIS factors associated with microin-
vasion or invasion.
Methods. The SLN procedure was performed during
mastectomy, and for positive SLN an ALND was per-
formed during the same intervention. A tissue microarray
containing DCIS lesions from the mastectomy specimens
was subsequently performed.
Results. From May 2008 to December 2010, 228 patients
were enrolled from 14 French cancer centers, including 192
eligible patients with pure DCIS on VAB and successful SLN
procedures. ALND was avoided for 51 [67 %; 95 % confi-
dence interval (CI), 56–77 %] of all the patients who had
microinvasive DCIS or DCIS associated with invasive carci-
noma at mastectomy and a negative SLN. Of the 192 patients,
76 (39 %) with VAB-diagnosed DCIS were upgraded after
mastectomy to micro (n = 20) or invasive disease (n = 56).
The rate of positive SLN for patients with DCIS on VAB was
14 %. High nuclear grade of DCIS was associated with greater
risk of microinvasion and invasion, and HER2-amplified DCIS
was associated with greater risk of invasion.
Conclusions. Underestimation of invasive components is
high when DCIS is diagnosed by VAB in patients undergoing
mastectomy. Upfront SLN for patients with VAB-diagnosed
extensive DCIS avoids unnecessary ALND for two-thirds of
patients with micro or invasive disease on mastectomy.
The incidence of ductal carcinoma in situ (DCIS) has
dramatically increased, reaching 14.6 % in France in 20091
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with the use of breast cancer screening programs. Although
mastectomy was the common treatment in the past,2 breast-
conserving surgery currently is used successfully. Exten-
sive DCIS is not considered in this category, and patients
often are recommended to undergo mastectomy. Vacuum-
assisted (VAB) biopsies frequently underestimate invasion,
with 5–20 % of VAB-diagnosed DCIS cases upstaged to
microinvasion or invasive carcinoma at the final pathologic
assessment.
Although the indication for sentinel lymph node (SLN)
biopsy in the DCIS setting is controversial, it is advised for
patients treated by mastectomy or when invasive disease is
suspected.3 However, no prospective clinical study has
ever assessed the pertinence of this strategy.
The SLN biopsy is a minimally invasive procedure, and
when results are negative, axillary lymph node dissection
(ALND),4,5 associated with higher morbidity rates,6,7 can
be avoided. When results are positive, ALND remains the
standard of care, but its use often has been called into
question. The ACOSOG Z0011 trial, for instance, has
shown that secondary ALND is not necessary for patients
with invasive carcinoma treated by conservative surgery
and presenting with fewer than two positive SLNs.8 Be-
cause mastectomy alters the lymphatic drainage of the
breast, axillary staging with SLN biopsy in the weeks after
surgery is no longer accurate, and ALND should be per-
formed systematically.4
This prospective multicenter study examined the rele-
vance of using the SLN procedure upfront for patients
with extensive microcalcifications on mammography and
treated by mastectomy. The primary end point was the
rate of needless ALND avoided for patients whose mas-
tectomy specimen showed DCIS with microinvasion
(DCIS–MI) or DCIS with invasive carcinoma (DCIS–
IDC). The secondary end points were the rate of under-
estimation of invasion by VAB, the discrepancy between
extension of microcalcifications on mammography and
DCIS histologic size, the rates of SLN detection and
positive SLN, and the identification of specific pathologic
and immunohistochemical factors of DCIS associated
with microinvasion and invasion.
METHODS
Patients
Patients were recruited from 14 participating French
comprehensive cancer centers. These patients were older
than 18 years and presented with extensive microcalcifi-
cations or multicentric foci (in two different quadrants) of
the breast classified as American College of Radiology
Breast Imaging-Reporting and Data System (ACR BI-
RADS) categories four or five on mammography and a
diagnosis of DCIS or DCIS–MI on VAB. The patients had
an indication for mastectomy jointly determined by a ra-
diologist and a surgeon because conservative treatment was
not feasible. Patients with lumpectomy-diagnosed DCIS or
DCIS–MI, previous ipsilateral radiation therapy or ALND,
previous in situ or invasive ipsilateral breast carcinoma, or
an indication for conservative breast surgery were excluded
from this study.
Mastectomy with an SLN procedure was performed as
described by Rodier et al.9 For each SLN detected, an in-
traoperative evaluation of frozen sections was performed.
For patients with positive SLN, an ALND was performed
during the same intervention.
This study was approved by the Committee of Protec-
tion of Individuals, Aquitaine, France and performed in
accordance with the Helsinki Declaration. All the par-
ticipants provided written informed consent (clinical trials
NCT01841749).
Pathologic Analysis
The participating centers used a standardized protocol
for handling SLN. Fresh, nonfixed SLNs were sent from
the operating room to the pathology laboratory for
macroscopic analysis. For grossly suspicious SLN, an in-
traoperative microscopic frozen section analysis was
performed. Otherwise, the SLNs were fixed, then grossly
sectioned at 2-mm intervals and paraffin-embedded in their
entirety.
Each formalin-fixed paraffin-embedded SLN block was
sectioned at three levels separated by 300 lm. For each
level, a hematoxylin and eosin (H&E) section and three
unstained slides were prepared. An immunohistochemical
analysis with a cytokeratin antibody was performed only if
suspicious nondeterminate cells were found on the H&E
section of the SLN.
The mastectomy specimens were X-rayed and drawn on
a centimeter grid to determine the correlation between the
initial mammographic findings and the histologic analyses.
Pathologic sampling was performed using the grid as a
template, and tissue blocks containing DCIS were reported
on the grid. The pathologic extent of DCIS then was
measured directly on the grid. The pathologist evaluated
the extent of the DCIS by radiography of the mastectomy
specimen.
For verification purposes, the mastectomy specimens
were X-rayed and drawn on a centimeter grid for estima-
tion of DCIS size by measurement of the distance between
the two furthermost blocks with DCIS involvement. The
presence of scar tissue corresponding to the previous
biopsy site was searched in every case.
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After completion of the study, a central pathology re-
view and a tissue microarray (TMA) were performed with
all mastectomy specimens. Other specific pathologic cri-
teria including the presence of necrosis, the nuclear grade
within the DCIS lesion, and the presence of a lympho-
plasmacytic infiltrate (inflammation) surrounding the DCIS
lesion were centrally assessed by a single pathologist
(G.M.G.). Pretherapeutic macrobiopsies were not available
for central pathologic review.
Immunohistochemical and Dual In Situ Hybridization
Analysis
Immunohistochemical analysis was performed on a Ven-
tana Benchmark Ultra automat (Meylan, France).
Supplementary Table S1 summarizes the technical conditions
and the antibodies used. Immunohistochemical staining was
estimated on the luminal cells in the mastectomy specimens,
either in the nuclei for ER, PR, FOXA1, and Ki-67; on the
cytoplasmic membrane for HER2, EGFR, and E-cadherin; or
in the cytoplasm for CK5/6, CK14, P16, and CSTA. For
E-cadherin, a continuous cytoplasmic membrane staining was
considered as positive. Any other type was considered nega-
tive. The threshold of positivity was 10 % for ER, PR, and
FOXA1 and 15 % for Ki-67. For assessment of Ki-67, a
semiquantitative method was used, in which the proportion of
Ki-67-positive DCIS cells in the overall DCIS cell population
was estimated on one histologic section regardless of the
number of ducts involved. The HER2 immunostaining was
interpreted according to the American Society of Clinical
Oncology (ASCO) scoring system applied to DCIS.10 The
number of positive DCIS cells per tissue section was deter-
mined semiquantitatively from 0 to 100 % as well as the
intensity of staining for E-cadherin, EGFR, P16, and CSTA. A
staining score of 0–300 was obtained by multiplying the
percentage of positive DCIS cells by their staining intensity. A
threshold of 100 was chosen to separate the positive EGFR,
P16, and CSTA cases from the negative ones, and a threshold
of 200 was chosen for E-cadherin. The presence or absence of
any staining for CK5/6 or CK14 was scored respectively as
positive or negative.
The epithelial membrane antigen (EMA) staining pat-
tern in the luminal cells of the DCIS lesions was recorded
in accordance with the classification of de Roos et al.11
Predominant diffuse cytoplasmic (CD), focal cytoplasmic
(CF), diffuse membranous (MD), and apical membranous
(MA) patterns of EMA staining were briefly specified.
Scoring of COX2 staining was performed according to
Kerlikowske et al.12 Dual ISH using the Ventana Inform
HER2 dual ISH was performed on a Ventana Benchmark
Ultra automat. In this study, DCIS was considered as
HER2-amplified when the absolute HER2 gene copy
number was 6 or higher and the HER2/CEN17 ratio was
2.2 or higher. All cases were analyzed for HER2 status by
dual ISH irrespective of their immunohistologic status.
Statistical Analysis
The primary end point of this study was the rate of
ALND avoided in patients with microinvasive DCIS or
DCIS associated with invasive carcinoma diagnosed in the
mastectomy specimen and the SLNs void of cancer. We
calculated the rate as the number of patients with negative
SLNs divided by the total number of patients with mDCIS–
MI or mDCIS–IDC.
To calculate the required number of patients, we pre-
dicted a 10 % underestimation of invasion on VAB. Of this
10 % requiring upstaging, approximately 80 % should
have negative SLNs. The rate of avoided ALND was thus
estimated to be about 8 % of the patients with DCIS and an
indication of mastectomy, and 100 patients were necessary
to obtain a corresponding 95 % confidence interval (CI) of
about 3.5–15.2 %.
The rate of discordance between VAB and mastectomy
was calculated by dividing the number of patients with
discordant results between VAB and surgery by the total
number of patients. The association between the extension
of microcalcifications shown on mammography and the
histologic size of DCIS in the mastectomy specimens was
analyzed using Spearman’s test.
Univariate analyses using v2, Fisher’s exact test, or Wil-
coxon’s rank sum test identified pretreatment radiologic and
postmastectomy pathologic and immunohistochemical fac-
tors associated with microinvasion and invasion in the
mastectomy specimen. All factors significant at a p value
lower than 0.15 were included in a multiple logistic regres-
sion model adjusted for age with a stepwise manual process.
Precisely, the following factors and categories were asses-
sed: DCIS radiologic and pathologic factors (histologic size,
continuous), nuclear grade (low, intermediate, or high),
necrosis (yes vs no), and inflammation (yes vs no), as well as
immunohistochemical factors (ER, PR, and FOXA1) (\10
vs C10 %); Ki-67 (\15 vs C15 %); HER2 (0 or ? vs
?? vs ???); CK5/6 and CK14 (positive vs negative);
EGFR, P16, or CSTA (\100 vs C100); E-cadherin (\200 vs
C200), EMA (CD?CF vs MA?MD); COX2 (0–1 vs 2–3);
and HER2 gene (amplified vs nonamplified). A p value lower
than 0.05 was considered statistically significant.
RESULTS
Inclusions and Initial VAB
Between May 2008 and December 2010, 228 women
with biopsy-diagnosed DCIS (bDCIS or bDCIS–MI) were
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included in the study. One major protocol violation was
excluded, leaving 227 patients eligible for analysis, in-
cluding 196 bDCIS and 31 bDCIS–MI patients (Fig. 1).
Table 1 presents the presurgical pathologic and radiologic
characteristics for the bDCIS after VAB diagnosis. Table 2
shows histologic characteristics from the mastectomy
specimen.
Rate of Unnecessary ALND Avoided
The SLN procedure was successful in identifying SLNs
in all but three cases (98 %), and no carcinoma was de-
tected in the mastectomy specimen for three patients,
giving a final population of 190 bDCIS patients. Figure 1
shows the results from the histologic analyses. A total of 76
initially pure bDCIS patients were upgraded to micro or
invasive events in the mastectomy specimen. Of these
patients, 51 had negative SLNs, and an unnecessary ALND
was therefore avoided (67 %; 95 % CI, 56–77 %). Of the
25 patients with SLN involvement, 15 underwent ALND [1
isolated tumor cell (ITC), 4 micrometastases, and 10
macrometastases]. In 10 cases (5 ITCs, 4 micrometastases,
and 1 macrometastasis), ALND was not performed. These
cases involved false-negative frozen section SLN results,
and local tumor boards decided not to perform subsequent
axillary clearance for clinical or patient preference reasons
(Table 3).
VAB Mastectomy Discrepancy Rate
Figure 1 illustrates the discrepancy between VAB and
mastectomy diagnoses. As shown, 39 % (76/196; 95 % CI,
45.8–32.1 %) of the patients with a diagnosis of bDCIS on
VAB were subsequently upgraded and, excluding the failed
SLN procedures (3/196) as well as the patients with
missing SLN data (1/196), the rate of positive SLN was
13 % (25/192).
A correlation was found between the extension of mi-
crocalcifications on mammography and the histologic size
of DCIS in the mastectomy specimens (q = 0.215;
















































FIG. 1 Flow chart of ductal carcinoma in situ (DCIS) patients
included in the study and results of the sentinel lymph node (SLN)
procedure. n number of patients, ALND axillary lymph node
dissection, VAB vacuum-assisted biopsy, b-DCIS vacuum-assisted
biopsy-diagnosed DCIS, b-DCIS–MI vacuum-assisted biopsy-
diagnosed DCIS with microinvasion, mDCIS mastectomy-diagnosed
DCIS, mDCIS–MI mastectomy-diagnosed DCIS with microinvasion,
mDCIS–IDC mastectomy-diagnosed DCIS with associated invasive
carcinoma
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Uni- and Multivariate Analyses of Pathologic
and Immunohistochemical Factors of DCIS
with Microinvasion or Invasion in the Mastectomy
Specimen
Pathologic and immunohistochemical factors of DCIS
associated with microinvasion in the univariate analyses
included the presence of inflammation, ER-negative status,
PR-negative status, the presence of necrosis, high nuclear
grade, a P16 score of 100 or higher, and a CSTA score of
100 or higher (Table 4). Only high nuclear grade remained
a significant independent factor in the multivariable model.
Pathologic and immunohistochemical factors of DCIS
associated with invasion in the univariate analyses included
the presence of inflammation, the presence of necrosis,
high nuclear grade, a predominant EMA membranous
staining pattern, amplification of HER2, and Ki-67 of 15 %
or higher. In the multivariable model, high nuclear grade
and amplification of HER2 were independent factors.
Supplementary Tables S2 and S3 provide further details on
the uni- and multivariate analyses.
TABLE 1 Presurgical pathologic and radiologic characteristics of
patients presenting with ductal carcinoma in situ (DCIS) diagnosed on
vacuum-assisted biopsy (VAB)
bDCIS (n = 196)
Median age: years (range) 53.4 (24–83)
ACR BI-RADS
BI-RADS 4 95 (48.5)
BI-RADS 5 96 (49.0)
Missing dataa 5 (2.5)













Missing dataa 97 (49.5)
DCIS ductal carcinoma in situ, VAB vacuum assisted biopsy, n num-
ber of patients, ACR BiRADS American College of Radiology-Breast
Imaging-Reporting and Data System
a Missing data is the pretherapeutic macrobiopsy were not available
for central pathological review
TABLE 2 Histologic characteristics of mastectomy specimens for
ductal carcinoma in situ (DCIS) diagnosed on vacuum-assisted biopsy
(VAB) patients
bDCIS (n = 196)
SLN detected 192 (98.5)
Negative SLN 165 (85.9)
Positive SLN 27 (14.1)
1 Positive SLN 20 (74.1)
2 Positive SLNs 6 (22.2)
3 or 4 Positive SLNs 1 (3.7)
Mastectomy histologic results
pT0 3 (1.5)
pT is (pure mDCIS) 117 (59.7)
pT1 mic (mDCIS–MI) 20 (10.3)














DCIS size: mm (range) 69.3 (4–180)




Histological subtype 56 (100)
IDC 53 (94.6)
Others 3 (5.4)
Size (invasive): mm (range) 9.3 (1–45)
pT1 50/56 (89.3)





bDCIS vacuum-assisted biopsy-diagnosed ductal carcinoma in situ,
VAB vacuum-assisted biopsy, n number of patients, SLN sentinel
lymph node, mDCIS mastectomy-diagnosed ductal carcinoma in situ,
mDCIS-MI mastectomy-diagnosed ductal carcinoma in situ with mi-
croinvasion, IDC invasive ductal carcinoma, mDCIS-IDC
mastectomy-diagnosed ductal carcinoma in situ with associated in-
vasive carcinoma
a Multifocal was defined as 2 or more foci of invasive carcinoma
separated by at least 2 mm
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DISCUSSION
Although standard in the diagnosis of breast and other
cancers, SLN biopsy is not justified for all DCIS patients13
because DCIS usually is considered noninvasive. Occa-
sionally, an increased risk of invasion exists, and SLN
biopsy should be performed to assess the involvement of
the axillary nodes. We present a prospective study on the
relevance of the SLN procedure for patients who have
extensive DCIS with microcalcifications on mammography
diagnosed by VAB and treated by mastectomy. We se-
lected three major predictive factors of disease upgrading
as patient inclusion criteria:14 extensive microcalcifica-
tions,15,16 mastectomy,4,5,17 and VAB diagnosis.18–20
The primary aim was to investigate whether the use of
SLN upfront could avoid ALND for patients who have
biopsy-diagnosed DCIS with associated micro or invasive
carcinoma and negative SLN. We found that 67 % (51/76)
of patients presenting with mDCIS–MI or mDCIS–IDC
had negative SLNs and avoided complete ALND.
Findings show that SLN status is important when an infil-
trative component is associated with the DCIS lesion. Whereas
a negative SLN rules out unnecessary ALND, a positive SLN
results in a complete ALND. In our study, ALND proved un-
necessary for patients presenting with ITC or micrometastases,
supporting previous work by Galimberti et al.21 However, six
nonsentinel nodes were found to be positive in 11 ALNDs
performed for patients with macrometastases. These results
TABLE 3 Needless axillary lymph node dissection (ALND) avoided in mDCIS–MI and mDCIS–IDC cases upgraded after mastectomy







ALND avoided in mDCIS–MI
or mDCIS–IDC
SLN status
Negative 112 16 35 51/51
Positive 2 4 21a 10/25b
ITC (B0.2 mm) 2 1 5 5/6
Micrometastasis (0.2 B 2 mm) 0 1 7 4/8
Macrometastasis ([2 mm) 0 2 9 1/11
a 1 SLN had missing data
b ALND not performed
bDCIS vacuum-assisted biopsy-diagnosed ductal carcinoma in situ, n number of patients, SLN sentinel lymph node, mDCIS mastectomy-
diagnosed ductal carcinoma in situ, mDCIS-MI mastectomy-diagnosed ductal carcinoma in situ with microinvasion, IDC invasive ductal
carcinoma, mDCIS-IDC mastectomy-diagnosed ductal carcinoma in situ with associated invasive carcinoma, ITC isolated tumour cell
TABLE 4 Uni- and multivariate analyses of pathologic and immunohistochemical factors of ductal carcinoma in situ (DCIS) with concurrent
microinvasion (DCIS–MI) and invasive carcinoma (DCIS–IDC) in the mastectomy specimen
mDCIS–MI mDCIS–IDC
Univariate analysis p Multivariate analysisa Univariate analysis p Multivariate analysisa
OR (95% CI) p OR (95 % CI) p
High nuclear grade 0.006 3.1 (1.4–7.0) 0.007 0.12 2.7 (1.3–5.6) 0.008
Inflammation 0.03 NS 0.09 NS
Necrosis 0.04 NS 0.05 NS
ER-negative 0.01 NS NS NS
CSTA score C100 0.02 NS NS NS
EMA predominant pattern NS NS 0.11 NS
PR-negative 0.096 NS NS NS
P16 score C100 0.14 NS NS NS
HER2 amplification NS NS 0.009 OR 3.7 (1.7–7.8) 0.001
Ki67 NS NS 0.05 NS
DCIS ductal carcinoma in situ, mDCIS-MI mastectomy-diagnosed ductal carcinoma in situ with microinvasion, mDCIS-IDC mastectomy-
diagnosed ductal carcinoma in situ with associated invasive carcinoma, n number of patients, SD standard deviation, CI confidence interval, NS
non-significant
a The final multivariate model was adjusted for age
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diverge from those of ACOSOG Z001, which apply to patients
treated by breast-conserving surgery followed by whole-breast
irradiation therapy.
All the patients in our series were treated by mastectomy
without radiotherapy. The low risk of positive SLN usually
reported for pure DCIS (0.39–13.7 %)17,20,22–26 was con-
firmed by this study, which showed SLN to be positive in
2 % (2/114 ITC) of cases. For mDCIS–IDC and mDCIS–
MI, the overall rate of positive SLN was 33 % (25/76) [or
25 % (19/7) excluding ITC], which is significantly higher
than the 6.2 % reported by Tada et al.25 for invasive car-
cinoma with extensive DCIS. A direct correlation exists
between invasive carcinoma size and SLN positivity.27 In
our series, the mean size of invasive carcinoma was
9.3 mm (89 % pT1) compared with less than 5 mm in the
series by Tada et al.25 In three large series, the authors
concluded that a microinvasive lesion shown on biopsy or
an invasive component shown by surgery significantly in-
creased the risk of positive SLN.16,28
We observed a high rate of underestimation of invasive
components (40 %) compared with rates observed across
other VAB-diagnosed series (11.2–21 %)29–32 which may
have been due to the heterogeneity in the extent of DCIS
across series.
In a study comparable with ours, Tan et al.33 observed a
similar upgrade rate of 33 % for 90 patients with extensive
DCIS treated by mastectomy for a DCIS having a mean size
of 62 mm. In a recent Canadian study, DCIS size was the
only predictor of underestimation, with an odds ratio (OR) of
1.92 (95 % CI, 1.65–2.24) per 1-cm increase in size.34 The
large size of DCIS lesions in our series (mean size, 69.3 mm)
might explain the high rate of underestimation compared
with others.15,18 Indeed, previous results15,16,20 have
demonstrated that DCIS size is an independent risk factor for
concomitant invasive carcinoma.16 Three patients were
overtreated with mastectomy because no DCIS was found on
the surgical specimen, and DCIS lesions were confirmed
after review of the VAB. The other microcalcifications found
on the mastectomy specimens were located in benign lesions.
Pathologic and immunohistochemical factors associated
with invasive components and DCIS are currently unknown.
Previous studies have examined the expression of different
markers in DCIS and the risk of subsequent in situ or invasive
recurrence.11,12 We therefore investigated the association
between their level of expression in the DCIS lesions and the
risk of invasive carcinoma. In univariate analyses, high
DCIS nuclear grade, necrosis, and stromal inflammation
were associated with both microinvasion and invasion.
However, after multivariate modeling, only high nuclear
grade was found to be associated with both events. Over-
expression of HER2 was an independent predictor of a higher
risk of invasive components. Amplification of HER2 in
DCIS is more frequent than in invasive carcinoma35,36 and
for some authors may represent a precursor of invasion37–39
In the NSABP B43 trial, transtuzumab was used as chemo-
preventive treatment for DCIS with HER2 amplification.39
Recently, CSTA, a protease inhibitor of cathepsin B
activity, was found to be downregulated in invasive carci-
nomas adjacent to DCIS.40 Surprisingly, we found high
levels of CSTA expression in DCIS to be associated with
micro invasion, which is somewhat contradictory with the
initial finding of Lee et al.40 who found that down regulation
of CSTA was associated with progression of DCIS to in-
vasive carcinoma. Our findings tend to indicate that DCIS is
a heterogeneous pathology that can either remain as pure
DCIS or progress to DCIS–MI or DCIS–IDC.
This study confirmed the relevance of the SLN procedure
and further encourages recommendation for patients with
DCIS diagnosed by VAB presenting with extensive micro-
calcifications on mammography and treated by mastectomy
because it avoids unnecessary ALND for patients with no
lymph involvement, ITC, or a single micrometastasis in
SLN. Additionally, in terms of staging, SLN biopsy sur-
passes the accuracy of VAB or mastectomy, with almost four
in ten DCIS diagnoses underestimated on the initial VAB and
upgraded after mastectomy. Our results also demonstrate
that whereas amplification of HER2 is an independent pre-
dictor of invasive disease, high nuclear grade is associated
with an increased risk of both microinvasion and invasion.
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